Duchenne Muscular Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Duchenne Muscular Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Report Format: PDF+Excel | Report ID: SR112025A31005

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
2.5       Forecasting Methodology
3 Executive Summary
4 Duchenne Muscular Dystrophy - Introduction

    4.1 Overview
    4.2 Regulatory Process
    4.3 Epidemiology (​2019-2024​) and Forecast (​2025-2035​)
    4.4 Market Overview (​2019-2024​) and Forecast (​2025-2035​)
    4.5 Competitive Intelligence
5 Duchenne Muscular Dystrophy - Disease Overview
    5.1    Introduction
    5.2    Symptoms and Diagnosis
    5.3    Pathophysiology
    5.4    Causes and Risk Factors
    5.5    Treatment
6 Patient Journey
7 Duchenne Muscular Dystrophy - Epidemiology and Patient Population

7.1    Epidemiology - Key Insights    
  7.2    Epidemiology Scenario - Top 7 Markets
           7.2.1 Epidemiology Scenario (​2019-2024​)     
           7.2.2 Epidemiology Forecast (​2025-2035​)    
           7.2.3 Epidemiology by Age (​2019-2035​)
           7.2.4 Epidemiology by Gender (​2019-2035​)
           7.2.5 Diagnosed Cases (​2019-2035​)
           7.2.6 Patient Pool/Treated Cases (​2019-2035​)    
    7.3    Epidemiology Scenario - United States    
        7.3.1 Epidemiology Scenario (​2019-2024​)    
        7.3.2 Epidemiology Forecast (​2025-2035​)    
        7.3.3 Epidemiology by Age (​2019-2035​)    
            7.3.4 Epidemiology by Gender (​2019-2035​)
    7.3.5 Diagnosed Cases (​2019-2035​)
        7.3.6 Patient Pool/Treated Cases (​2019-2035​)
    7.4    Epidemiology Scenario - Germany    
        7.4.1 Epidemiology Scenario (​2019-2024​)    
        7.4.2 Epidemiology Forecast (​2025-2035​)    
        7.4.3 Epidemiology by Age (​2019-2035​)
    7.4.4 Epidemiology by Gender (​2019-2035​)
           7.4.5 Diagnosed Cases (​2019-2035​)
           7.4.6 Patient Pool/Treated Cases (​2019-2035​)    
     7.5    Epidemiology Scenario - France            
              7.5.1 Epidemiology Scenario (​2019-2024​)
        7.5.2 Epidemiology Forecast (​2025-2035​)
        7.5.3 Epidemiology by Age (​2019-2035​)
    7.5.4 Epidemiology by Gender (​2019-2035​)
            7.5.5 Diagnosed Cases (​2019-2035​)
            7.5.6 Patient Pool/Treated Cases (​2019-2035​)    
    7.6     Epidemiology Scenario - United Kingdom
        7.6.1 Epidemiology Scenario (​2019-2024​)    
        7.6.2 Epidemiology Forecast (​2025-2035​)    
        7.6.3 Epidemiology by Age (​2019-2035​)    
        7.6.4 Epidemiology by Gender (​2019-2035​)    
        7.6.5 Diagnosed Cases (​2019-2035​)
        7.6.6 Patient Pool/Treated Cases (​2019-2035​)    
    7.7    Epidemiology Scenario - Italy    
        7.7.1 Epidemiology Scenario (​2019-2024​)    
        7.7.2 Epidemiology Forecast (​2025-2035​)    
        7.7.3 Epidemiology by Age (​2019-2035​)    
        7.7.4 Epidemiology by Gender (​2019-2035​)    
        7.7.5 Diagnosed Cases (​2019-2035​)
        7.7.6 Patient Pool/Treated Cases (​2019-2035​)    
    7.8    Epidemiology Scenario - Spain    
        7.8.1 Epidemiology Scenario (​2019-2024​)    
        7.8.2 Epidemiology Forecast (​2025-2035​)    
        7.8.3 Epidemiology by Age (​2019-2035​)    
        7.8.4 Epidemiology by Gender (​2019-2035​)    
        7.8.5 Diagnosed Cases (​2019-2035​)
         7.8.6 Patient Pool/Treated Cases (​2019-2035​)    
    7.9    Epidemiology Scenario - Japan    
        7.9.1 Epidemiology Scenario (​2019-2024​)    
        7.9.2 Epidemiology Forecast (​2025-2035​)    
        7.9.3 Epidemiology by Age (​2019-2035​)
        7.9.4 Epidemiology by Gender (​2019-2035​)
        7.9.5 Diagnosed Cases (​2019-2035​)
        7.9.6 Patient Pool/Treated Cases (​2019-2035​)    
8 Duchenne Muscular Dystrophy Treatment - Treatment Algorithm, Guidelines, and Medical Practices
    8.1    Guidelines, Management and Treatment
    8.2    Treatment Algorithm    
9 Duchenne Muscular Dystrophy Treatment - Unmet Needs
10 Duchenne Muscular Dystrophy Treatment - Key Endpoints of Treatment
11 Duchenne Muscular Dystrophy Treatment - Marketed Products    

    11.1 List of Duchenne Muscular Dystrophy Treatment - Marketed Drugs Across the Top 7 Markets    
11.1.1 Duvyzat (givinostat) - Italfarmaco
           11.1.1.1 Drug Overview    
           11.1.1.2 Mechanism of Action    
           11.1.1.3 Clinical Trial Results    
           11.1.1.4 Safety and Efficacy
           11.1.1.5 Regulatory Status    
   11.1.2 Elevidys (delandistrogene moxeparvovec-rokl) - Sarepta Therapeutics           
           11.1.2.1 Drug Overview    
           11.1.2.2 Mechanism of Action    
           11.1.2.3 Clinical Trial Results    
            11.1.2.4 Safety and Efficacy
            11.1.2.5 Regulatory Status
    11.1.3 Emflaza (deflazacort) - Marathon Pharmaceuticals/PTC Therapeutics
               11.1.3.1 Drug Overview    
               11.1.3.2 Mechanism of Action    
               11.1.3.3 Clinical Trial Results    
              11.1.3.4 Safety and Efficacy
              11.1.3.5 Regulatory Status
      11.1.4 PTC124 (Ataluren) - PTC Therapeutics
                11.1.4.1 Drug Overview    
                11.1.4.2 Mechanism of Action    
                11.1.4.3 Clinical Trial Results    
                11.1.4.4 Safety and Efficacy
                11.1.4.5 Regulatory Status
      11.1.5 Eteplirsen (Exondys 51) - Sarepta Therapeutics
                 11.1.5.1 Drug Overview    
                11.1.5.2 Mechanism of Action    
                11.1.5.3 Clinical Trial Results    
                11.1.5.4 Safety and Efficacy
                11.1.5.5 Regulatory Status

Complete list to be provided in the final report.

12 Duchenne Muscular Dystrophy Treatment - Pipeline Products
      12.1 List of Duchenne Muscular Dystrophy Treatment Pipeline Drugs Across the Top 7 Markets   
         12.1.1 RGX-202 - REGENXBIO 
                12.1.1.1 Drug Overview    
                12.1.1.2 Mechanism of Action    
                12.1.1.3 Clinical Trial Results    
                12.1.1.4 Safety and Efficacy
                12.1.1.5 Regulatory Status
         12.1.2 Sevasemten (EDG-5506) - Edgewise Therapeutics
                12.1.2.1 Drug Overview
                12.1.2.2 Mechanism of Action
                12.1.2.3 Clinical Trial Results
                12.1.2.4 Safety and Efficacy  
                12.1.2.5 Regulatory Status

Complete list to be provided in the final report.

13 Duchenne Muscular Dystrophy Treatment - Attribute Analysis of Key Marketed and Pipeline Drugs    
14 Duchenne Muscular Dystrophy Treatment – Clinical Trial Landscape

    14.1 Drugs by Status
    14.2 Drugs by Phase
    14.3 Drugs by Route of Administration
    14.4 Key Regulatory Events    
15 Duchenne Muscular Dystrophy Treatment Market Scenario    
  15.1    Market Scenario - Key Insights    
  15.2    Market Scenario - Top 7 Markets  
         15.2.1 Duchenne Muscular Dystrophy Treatment - Market Size         
                  15.2.1.1 Market Size (​2019-2024​)    
                  15.2.1.2 Market Forecast (​2025-2035​)
         15.2.2 Duchenne Muscular Dystrophy Treatment - Market Size by Therapies     
                  15.2.2.1 Market Size by Therapies (​2019-2024​)
                  15.2.2.2 Market Forecast by Therapies (​2025-2035​)
 15.3    Market Scenario - United States    
        15.3.1 Duchenne Muscular Dystrophy Treatment - Market Size
                  15.3.1.1 Market Size (​2019-2024​)    
                 15.3.1.2 Market Forecast (​2025-2035​)
        15.3.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies
                 15.3.2.1 Market Size by Therapies (​2019-2024​)                 
                 15.3.2.2 Market Forecast by Therapies (​2025-2035​)    
        15.3.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview
   15.4    Market Scenario - Germany    
          15.4.1 Duchenne Muscular Dystrophy Treatment - Market Size    
                 15.4.1.1 Market Size (​2019-2024​)    
                 15.4.1.2 Market Forecast (​2025-2035​)    
        15.4.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies
                 15.4.2.1 Market Size by Therapies (​2019-2024​)                        
                15.4.2.2 Market Forecast by Therapies (​2025-2035​)
        15.4.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview        
   15.5    Market Scenario - France    
         15.5.1 Duchenne Muscular Dystrophy Treatment - Market Size    
                 15.5.1.1 Market Size (​2019-2024​)    
                 15.5.1.2 Market Forecast (​2025-2035​)    
       15.5.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies    
                  15.5.2.1 Market Size by Therapies (​2019-2024​)               
                  15.5.2.2 Market Forecast by Therapies (​2025-2035​)
        15.5.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview 
   15.6    Market Scenario – United Kingdom
        15.6.1 Duchenne Muscular Dystrophy Treatment - Market Size    
                  15.6.1.1 Market Size (​2019-2024​)    
                 15.6.1.2 Market Forecast (​2025-2035​)
         15.6.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies    
                  15.6.2.1 Market Size by Therapies (​2019-2024​)
          15.6.2.2 Market Forecast by Therapies (​2025-2035​)
        15.6.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview 
    15.7    Market Scenario – Italy
          15.7.1 Duchenne Muscular Dystrophy Treatment - Market Size
                  15.7.1.1 Market Size (​2019-2024​)    
                    15.7.1.2 Market Forecast (​2025-2035​)    
      15.7.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies 
                  15.7.2.1 Market Size by Therapies (​2019-2024​)    
                   15.7.2.2 Market Forecast by Therapies (​2025-2035​) 
         15.7.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview 
    15.8    Market Scenario - Spain
          15.8.1 Duchenne Muscular Dystrophy Treatment - Market Size
                 15.8.1.1 Market Size (​2019-2024​)
               15.8.1.2 Market Forecast (​2025-2035​)    
         15.8.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies
                 15.8.2.1 Market Size by Therapies (​2019-2024​)    
                 15.8.2.2 Market Forecast by Therapies (​2025-2035​)
        15.8.3 Duchenne Muscular Dystrophy Treatment- Access and Reimbursement Overview 
    15.9    Market Scenario - Japan    
            15.9.1 Duchenne Muscular Dystrophy Treatment - Market Size
                 15.9.1.1 Market Size (​2019-2024​)    
                 15.9.1.2 Market Forecast (​2025-2035​)              
         15.9.2 Duchenne Muscular Dystrophy Treatment- Market Size by Therapies
                  15.9.2.1 Market Size by Therapies (​2019-2024​)
                  15.9.2.2 Market Forecast by Therapies (​2025-2035​)
         15.9.3 Duchenne Muscular Dystrophy Treatment - Access and Reimbursement Overview 
16 Duchenne Muscular Dystrophy Treatment - Recent Events and Inputs From Key Opinion Leaders
 17 Duchenne Muscular Dystrophy Treatment Market - SWOT Analysis    

   17.1    Strengths    
   17.2    Weaknesses    
   17.3    Opportunities    
   17.4    Threats    
18 Duchenne Muscular Dystrophy – Strategic Recommendations        
19 Appendix

Duchenne Muscular Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials